V8 Peptides — Engineered Performance
Research Library
CJC-1295 DAC and Ipamorelin Stack: GH-Axis Research
CJC-1295 DACComparison

CJC-1295 DAC and Ipamorelin Stack: GH-Axis Research

V8 Peptides Research TeamUpdated

Compiled from peer-reviewed literature and manufacturer analytical data for laboratory research reference.

Quick answer

What does pairing CJC-1295 with ipamorelin test? It pairs a GHRH-receptor ligand (Gs, cAMP) with a ghrelin-receptor ligand (Gq, calcium) on the same pituitary cell, asking whether activating both differs from either alone. CJC-1295 with DAC binds albumin and persists for days in animal models, while the no-DAC form is brief, so the form chosen sets the kinetics of the design. V8 stocks the no-DAC form and a 1:1 mass blend, which is roughly 4.7 ipamorelin to 1 CJC-1295 by moles. For laboratory research use only.

The phrase "CJC-1295 DAC and ipamorelin stack" combines two different questions: which form of CJC-1295 is meant, and what a laboratory learns by pairing a growth-hormone-releasing-hormone (GHRH) analog with a ghrelin-receptor agonist. This article handles both as design questions. It explains the two receptors, why the DAC and no-DAC forms of CJC-1295 have opposite kinetics and therefore suggest different experiments, how to do the mass-versus-molar arithmetic for a 1:1 mass blend, and which controls a two-receptor study needs. It is a research-design discussion of published preclinical science only and makes no claim about outcomes. The materials are for laboratory research use only; not for human consumption.

Two receptors, two pathways

Growth-hormone (GH) release from pituitary somatotrophs is controlled by more than one input. Two of them are relevant here.

PropertyGHRH receptorGHS-R1a (ghrelin receptor)
---------
Natural ligandGrowth-hormone-releasing hormoneGhrelin
Receptor classClass B GPCRClass A GPCR
Main signalingGs, adenylyl cyclase, cAMPPredominantly Gq, phospholipase C, intracellular calcium
Laboratory ligand in this contextCJC-1295 (DAC or no DAC)Ipamorelin
Reference workMod GRF 1-29 and albumin-conjugate studiesCloning and secretagogue characterization

The ghrelin-receptor side has a clear origin story. Bowers and colleagues described synthetic hexapeptides that released GH in vitro and in vivo in the 1980s (Bowers et al., 1984), and the receptor through which such secretagogues act was identified by Howard and colleagues (1996) and cloned in the pituitary and hypothalamus; Pong and colleagues (1996) described the new G-protein-linked receptor for growth hormone secretagogues. Ipamorelin was later characterized by Raun and colleagues (1998) as a selective secretagogue in pituitary cells and animals. The structure is the pentapeptide Aib-His-D-2-Nal-D-Phe-Lys-NH2, with a molecular formula of C38H49N9O5 as listed on the V8 ipamorelin product page.

Two receptors with different second-messenger systems converging on the same cell is the reason pairings are of interest: the experiment can ask whether activating both produces a response that differs from activating either alone.

DAC versus no DAC: opposite kinetics

CJC-1295 exists in two forms that differ by one chemical group. The no-DAC form, also called modified GRF(1-29), carries four substitutions that protect it from proteases, and its signal is brief. The DAC form adds a maleimide-bearing drug affinity complex through a lysine, which bonds covalently to serum albumin and extends persistence from minutes to days in animal models; Jetté and colleagues (2005) reported the albumin-bioconjugate approach for GRF(1-29). The CJC-1295 with DAC research overview explains the chemistry, and CJC-1295 DAC versus no DAC compares the two directly.

FeatureCJC-1295 no DACCJC-1295 with DAC
---------
Albumin bindingNoneCovalent, through the DAC group
Persistence in animal modelsMinutes to tens of minutesHours to days
Receptor signal shapeBrief, pulse-likeSustained
Typical design usePulse-type studies, onset and decayPersistent-exposure studies
Availability at V8Listed as a productNot currently stocked

V8 supplies the no-DAC form, on the CJC-1295 (No DAC) page, and a co-lyophilized CJC-1295 (No DAC) + ipamorelin blend. The DAC form is not stocked, so anyone planning DAC work should be aware that the comparison material on this site is the no-DAC analog.

Why the kinetics matter for a pairing

Endogenous GH secretion is pulsatile. A design that pairs a persistent GHRH-receptor ligand with a short-acting secretagogue combines two different signal shapes: one receptor is continuously occupied while the other is activated briefly. That is a legitimate question, but it is not the same question as pairing two short-acting compounds, and a result from one design cannot be read as a result from the other.

The matched-kinetics design, no-DAC with ipamorelin, lets both receptors be stimulated at the same time and fall silent at roughly the same time. It suits pulse-type experiments on onset, peak and recovery. The mismatched design, DAC with ipamorelin, asks how a pulse at the ghrelin receptor plays out against a background of continuing GHRH-receptor signal. It also raises questions about receptor desensitization that a brief stimulus does not.

The arithmetic of a 1:1 mass blend

The V8 blend page describes a 1:1 mass ratio, supplied as 5 mg of each (10 mg total) or 10 mg of each (20 mg total). A mass ratio is not a molar ratio.

CompoundApproximate molecular weightMoles per 5 mg
---------
CJC-1295 no DAC (Mod GRF 1-29)≈ 3,368 g/mol≈ 1.48 µmol
Ipamorelin≈ 712 g/mol≈ 7.02 µmol

Dividing the larger number by the smaller gives about 4.7 ipamorelin molecules per CJC-1295 molecule. Any statement that a blend contains "equal amounts" is therefore a statement about mass. If an experiment is designed around receptor occupancy, convert with the formula moles equal mass divided by molecular weight, and prepare comparison arms accordingly. Mass concentration is vial mass divided by diluent volume, and the reconstitution calculator does that part. Per-product tables are intentionally omitted: the calculator is the single place for the figures.

Controls for a two-receptor design

ArmPurpose
------
VehicleBaseline and diluent effect
GHRH analog aloneThe contribution of the GHRH receptor
Ipamorelin aloneThe contribution of the ghrelin receptor
Both togetherThe pairing under test
Receptor antagonist for each pathwayConfirms each contribution is receptor-mediated
Matched-kinetics versus mismatched-kinetics pairIsolates the effect of persistence from the effect of pairing

The final row is the design contribution that the DAC question makes possible. If both forms of CJC-1295 are available in the laboratory, running both with ipamorelin under identical conditions separates persistence from pairing. The CJC-1295 and ipamorelin blend versus separate vials article discusses the blend format in the same terms.

Where this sits among other metabolic-axis tools

The growth-hormone axis is one of several endocrine systems studied with receptor-selective peptides. A useful contrast is retatrutide, whose product page describes a triple GIP, GLP-1 and glucagon receptor agonist: three receptors of the same class B family hit by one molecule. The CJC-1295 and ipamorelin pairing is the opposite design, two molecules each selective for one receptor, from two different receptor classes. Whether one multi-target molecule or two single-target molecules is the better tool depends on the question, and the retatrutide research overview discusses the single-molecule side. In the pairing case the experimenter controls the ratio and timing independently, which is the main advantage of two separate compounds and the reason the controls in the table above are possible at all.

Measurement considerations

GH is secreted in pulses, so a single time point is a poor measurement; sampling frequency should be set by the expected pulse shape. In cell systems, cAMP is the natural readout for the GHRH receptor and intracellular calcium for the ghrelin receptor, which allows the two pathways to be measured separately in the same cells. Species matters for GH immunoassays, because antibodies differ in cross-reactivity. Earlier characterizations of GRF fragments in a mouse model (Clark and colleagues, 1985) illustrate how species-specific the in vivo systems are.

Reading a pairing claim critically

Claims about pairings circulate widely, and a few questions sort them quickly. Which receptors are named, and are they the two discussed above? Which form of CJC-1295 is meant, since DAC and no-DAC are different tools? Is the claim about a pulse, a baseline or an integrated readout? Were single-compound arms run? And is the amount stated by mass or by moles? A claim that cannot answer these is a statement about a product category, not a result. Keeping this checklist next to the literature saves effort, and it makes it clear which gaps in the published record a new experiment could actually fill.

Handling the blend

The blend is a lyophilized powder; the product page gives storage at 2–8 °C, or −20 °C for long-term, with protection from heat, moisture and light. For dissolution and storage details, see CJC-1295 and ipamorelin reconstitution and storage; for the underlying compounds, the ipamorelin research overview and the CJC-1295 and ipamorelin research overview. Quality documentation is covered in CJC-1295 and ipamorelin purity testing, and certificates are listed in the COA library where published.

Frequently asked questions

What is the difference between CJC-1295 with DAC and without DAC?

The DAC form carries a maleimide group that bonds to serum albumin, extending persistence in animal models from minutes to days. The no-DAC form, modified GRF(1-29), has no albumin binding and produces a brief, pulse-like signal.

Does V8 stock CJC-1295 with DAC?

Not currently. V8 lists the no-DAC form and a no-DAC plus ipamorelin blend for laboratory research use only.

Which receptors do CJC-1295 and ipamorelin act on?

CJC-1295 acts on the GHRH receptor, which signals mainly through Gs and cAMP. Ipamorelin acts on the ghrelin receptor GHS-R1a, which signals predominantly through Gq and intracellular calcium.

Is a 1:1 blend equal in molecules?

No. It is equal in mass. Ipamorelin is much smaller than CJC-1295, so a 1:1 mass blend holds roughly 4.7 ipamorelin molecules per CJC-1295 molecule.

Why does kinetic mismatch matter in a pairing study?

Pairing a persistent GHRH-receptor ligand with a short-acting secretagogue combines different signal shapes, so results cannot be compared with a matched short-acting pair.

How should pulsatile GH release be measured?

With sampling frequent enough to capture the pulse shape, rather than a single time point, and with an immunoassay validated for the species being studied.

Which controls does a two-receptor study need?

Vehicle, each compound alone, both together, receptor antagonists for each pathway and, if both CJC-1295 forms are available, matched- and mismatched-kinetics pairs.

How is the concentration of each compound in the blend calculated?

Divide each compound's mass in the vial by the diluent volume. Use the reconstitution calculator for the arithmetic and convert to moles with molecular weights for receptor-based designs.

How is the blend stored?

As a lyophilized powder at 2–8 °C, or −20 °C for long-term, protected from heat, moisture and light, per the product page.

Related reading: CJC-1295 with DAC: Complete Chemistry Guide.

References

  1. Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-561. doi:10.1530/eje.0.1390552
  2. Jetté L, Léger R, Thibaudeau K, et al. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005;146(7):3052-3058. doi:10.1210/en.2004-1286
  3. Howard AD, Feighner SD, Cully DF, et al. A receptor in pituitary and hypothalamus that functions in growth hormone release. Science. 1996;273(5277):974-977. doi:10.1126/science.273.5277.974
  4. Pong SS, Chaung LY, Dean DC, et al. Identification of a new G-protein-linked receptor for growth hormone secretagogues. Mol Endocrinol. 1996;10(1):57-61. doi:10.1210/mend.10.1.8838145
  5. Bowers CY, Momany FA, Reynolds GA, Hong A. On the in vitro and in vivo activity of a new synthetic hexapeptide that acts on the pituitary to specifically release growth hormone. Endocrinology. 1984;114(5):1537-1545. doi:10.1210/endo-114-5-1537
  6. Clark RG, Robinson ICAF. Effects of a fragment of human growth hormone-releasing factor in normal and 'Little' mice. J Endocrinol. 1985;106(1):1-5. doi:10.1677/joe.0.1060001

Research Use Only. All products are sold strictly for laboratory research and development purposes only. Not for human or animal consumption. Not a drug, food, or cosmetic. By purchasing, you affirm you are a qualified researcher or institution.